Hungarian pharmaceutical company Gedeon Richter on Wednesday said it signed a strategic research collaboration and option-to-license agreement with Swiss biotech company FimmCyte.
Richter said the partnership aims to advance the development of FimmCyte's FMC2 antibody for the treatment of endometriosis.
The parties have negotiated an exclusive and worldwide license agreement for the future development and commercialization of the antibody. The license will automatically become effective if Richter exercises its option at any time prior to the initiation of the first-in-human clinical study. FimmCyte will be eligible for development and commercial milestone payments, together with tiered royalties on net sales.
The collaboration builds on Richter's recent expansion of its novel drug development capabilities, including the establishment of its women's health original research and development hub in Belgium, which will serve as a key centre for advancing the program.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Genius Automotive Hungarian Subsidiary's CEE Expansion November 2, 2025
